Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly

Ischemic Stroke

Neurological Injury

Stroke, Acute

Inflammatory Response

Permanent Injury

Neurologic Dysfunction

Neurological Disorder

Brain Ischemia

Brain Injuries

Omega-3 fish oil

Omega 3 and Ischemic Stroke; Fish Oil as an Option

The Potential Effect of Omega3 Supplement in Fish Oil on Infarced Areas in the Brain and Improvement of Neurological Functions fo Ischemic Stroke Patients

will be assessed by square centimetres on MRI scan

Assessed by National Institutes of Health Stroke Scale. The scale range is from 0 to 42 as following:
0 No stroke symptoms
1-4 Minor stroke
5-15 Moderate stroke
16-20 Moderate to severe stroke
21-42 Severe stroke

Assessed by the modified Rankin Scale. The scale consists of degrees from 0 to 6 as following:
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability
- Moderate disability.
- Moderately severe disability
- Severe disability
- Dead.

Nouf Al Mansour

Subspecialty Consultant Neurologist And Stroke Specialist

King Fahad Medical City

Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content

Post-Traumatic Headache Chronic Without Intractable Headache

The intervention will be administered through food products rather than dietary supplements

Diet/nutrition intervention

Medline Plus related topic: Traumatic Brain Injury

Medline Plus related topic: Post-traumatic headache

Walter Reed National Military Medical Center

Womack Army Medical Center (WAMC)

Fort Belvoir Community Hospital

Nutrition for Post-Traumatic Headache

Targeted Alteration in Omega-3 and Omega-6 Fatty Acids for Post-traumatic Headache (Nutrition for PTH)

Up to 300 participants complete the Headache Impact Test (HIT-6)—a headache-specific quality of life measure 6 times while enrolled in the study. The primary outcome measure is the change in the HIT-6 scores at baseline and at the end of the diet intervention.

All study participants will have blood drawn 3 times during the 16-week study for analysis of circulating fatty acids and their bioactive metabolites. The following fatty acids will be measured in each blood sample (ng or pg per mL): 17-hydroxy-DHA (docosahexaenoic acid), 18-Hydroxy-EPA (eicosapentaenoic acid), 9-HODE (hydroxyl-octadecadienoic acid), 13-ODE (octadecadienoic acid), 5-HETE (hydroxyl-eicosatetraenoic acid), 8-HETE, 9-HETE, 11-HETE. Changes in 17-hydroxy-DHA and related fatty acids levels between blood draws at baseline and at the end of the 12-week diet intervention will be compared with changes in headache frequency and severity at the same time points.

Up to 300 participants complete a headache diary daily while enrolled in the 16-week study. Participants record the total number of headache hours per day. The outcome measure is the change in the mean daily headache hours at baseline and at the end of the diet intervention between the H3-L6 and L3-H6 diet intervention groups.

Compared to the Control Diet, the H3-L6 Diet may produce significant improvement in non-headache pain. A survey of pain, the Total Body Pain Scale, will be administered at baseline and at the end of the 12-week diet intervention. The outcome measure is a reduction in non-headache pain as measured by the survey at baseline and at the end of the diet intervention.

Compared to the Control Diet, the H3-L6 Diet may produce significant improvement in: Use of acute pain medications. Participants will daily record all pain medications used in that 24-hour period. The outcome measure is the change in the acute pain medications sued at baseline and at the end of the diet intervention between the H3-L6 and L3-H6 diet intervention groups.

Compared to the Control Diet, the H3-L6 Diet may produce significant improvement in sleep quality. A sleep quality survey, the PSQI, will be administered at baseline at and the end of the 12-week diet intervention. The outcome measure is the change in the PSQI score at baseline and at the end of the diet intervention between the H3-L6 and L3-H6 diet intervention groups.

The PROMIS-29, a survey of psychological distress (depression/anxiety), will be administered at baseline and at the end of the 12-week diet intervention. The outcome measure is a reduction in depression and/or anxiety as measured by the PROMIS-29 at baseline and at the end of the diet intervention.

Compared to the Control Diet, the H3-L6 Diet may produce significant improvement in symptoms of post-traumatic stress disorder (PTSD). The PCL-C, a survey of post-traumatic stress symptoms, will be administered at baseline and at the end of the 12-week diet intervention. The outcome measure is the reduction in the PCL-C score at baseline and at the end of the diet intervention between the H3-L6 and L3-H6 diet intervention groups.

Compared to the Control Diet, the H3-L6 Diet may produce significant improvement in post-concussive symptoms. The Neurobehavioral Symptom Inventory (NSI) and the Glasgow Outcome Score-Extended (GOS-E) will be administered at baseline and at the end of the 12-week diet intervention. The outcome measure is a change in the NSI and GOS-E score at baseline and at the end of the diet intervention between the H3-L6 and L3-H6 diet intervention groups.

Study data to be uploaded into Federation Interagency Traumatic Brain Injury Repository (FITBIR) and made accessible after study is completed

Kimbra Kenney

Associate Professor, Neurology

Uniformed Services University of the Health Sciences

Womack Army Medical Center

University of North Carolina, Chapel Hill

National Institutes of Health (NIH)

Omega-3 fatty acid ethyl esters, 2 soft gels of total 1000mg (660mg EPA +340mg DHA)/day.

210mg of Omega-7 fatty acid and 1000mg (660mg EPA +340mg DHA) of Omega-3

Inflammation

Ingestion of omega 7 + 3 daily for 8 weeks.

Omega 7 + 3

Omega 3

Placebo

Appalachian State University Human Performance Lab, North Carolina Research Campus

Omega 7 + 3 Combination and Systemic Inflammation

Influence of Omega 7 + 3 Combination on Systemic Inflammation and Plasma Lipoproteins in Women: a 2-month, Double Blind, Placebo-Controlled, Randomized Community Trial

Effects of 8-weeks supplementation with omegas 7 and 3 fats combination versus omega-3 fats and placebo on systemic inflammation (CRP and cytokine panel).

Effects of 8-weeks supplementation with omegas 7 and 3 fats combination versus omega-3 fats and placebo on plasma lipoprotein panel.

Appalachian State University

The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.

The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.

Concussion

Mild Traumatic Brain Injury

Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.

Docosahexaenoic acid (DHA)

Sports Medicine at Texas Scottish Rite Hospital for Children

DHA For The Treatment of Pediatric Concussion Related to Sports Injury

Docosahexaenoic Acid (DHA) For The Treatment of Pediatric Concussion Related to Sports Injury

Determine the willingness of patients to be randomized, the expected rate of enrollment based on the clinic population, and protocol adherence of enrolled study participants.

Time to clearance to return to play (in days). Time to clearance to return to play was chosen as a clinically significant measurement for medical professionals in the sports medicine field. The investigators will determine clearance for return to full competitive game play (Stage 6 of graduated return to play protocol) according to Consensus Statement guidelines and following the law in Texas, House Bill 2038. Criteria for return to play include complete clinical recovery from the concussion including returning to baseline symptoms, exam and neurocognitive function and successful completion of a gradual return to play progression. We hypothesize that subjects who take 2 g of DHA daily for 3 months will see a shorter time to full recovery and return to play.

Improvement in balance impairment associated with the injury, as assessed by the Balance Error Scoring System (BESS) which is a component of the Sport Concussion Assessment Tool 3 (SCAT-3). We hypothesize a shorter time to resolve balance disturbance associated with the treatment of DHA.

docosahexaenoic acid/cefalea

Omega 3 and Ischemic Stroke; Fish Oil as an Option

Nutrition for Post-Traumatic Headache

Omega 7 + 3 Combination and Systemic Inflammation

DHA For The Treatment of Pediatric Concussion Related to Sports Injury

Il database di erbe medicinali più completo supportato dalla scienza